Intervention not reported
Etanercept (10 mg) · participants with rheumatoid arthritis
1 finding from 1 review
- no estimate extracted1 study · 425 participantsHigh
Findings
What do systematic reviews say?
72 questions · 73 findings · 8 reviews
No studies found 27 · 37%GRADE not reported 8 · 11%Very low 0 · 0%Low 9 · 12.3%Moderate 14 · 19.2%High 15 · 20.5%
Intervention not reported
Etanercept (25 mg) · participants with rheumatoid arthritis
1 finding from 1 review
- no estimate extracted1 study · 424 participantsHigh
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.97 [0.89, 1.07]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.93 [0.77, 1.11]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 2.94 [0.12, 70.67]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.98 [0.76, 1.27]Studies not reportedModerate
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1.12 [0.97, 1.29]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1 [0.8, 1.27]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 2.66 [1.07, 6.59]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyPeto OR 2.45 [0.55, 10.97]Studies not reportedLow
Etanercept vs Placebo (subcutaneous)
Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
- Melikoglu 2005 (etanercept 25 mg s.c. twice weekly for 4 weeks vs placebo, 40 male patients; high risk of reporting bias): authors reported a statistically significant difference in mean number of oral ulcers with…1 study · 40 participantsGRADE not reported
Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
- SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…Studies not reportedGRADE not reported
Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
- SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…Studies not reportedGRADE not reported
Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
- SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…Studies not reportedGRADE not reported
Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
- SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…Studies not reportedGRADE not reported
Any systemic treatment vs placebo
Etanercept · people with chronic plaque psoriasis
Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).
2 findings from 1 review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes onlyRR 9.72 [8.12, 11.63]14 studies · 5650 participantsModerate
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes onlyRR 0.89 [0.61, 1.31]13 studies · 4265 participantsModerate
Intervention not reported
ACR50 American College of Rheumatology 50% improvement criteria · participants with rheumatoid arthritis and with a partial response to DMARDs
The intervention probably leads to higher ACR50 American College of Rheumatology 50% improvement criteria (moderate certainty).
1 finding from 1 review
- RR 1.96 [1.33, 2.89]4 studies · 1198 participantsModerate
Intervention not reported
Reduction in disability score Health Assessment Questionnaire (mean improvement from baseline). Scale from: 0 to 3 · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review
- no estimate extracted1 study · 89 participantsModerate
Intervention not reported
Radiographic progression Total Sharp Score · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Intervention not reported
Withdrawals due to adverse events · participants with rheumatoid arthritis and with partial response to MTX
The intervention showed no clear difference in withdrawals due to adverse events (moderate certainty).
1 finding from 1 review
- RR 1.02 [0.1, 10.77]1 study · 89 participantsModerate